Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces greater weight reduction than GLP-1 monotherapy in individuals with obesity without type 2 diabetes.
Tirzepatide 15 mg injected once weekly leads to an average 20.9% body weight loss in adults with obesity without diabetes over 72 weeks. This dual-action hormone therapy is more effective than GLP-1 monotherapy.
StrongSupportsVERY_HIGH confidence
The SURMOUNT-1 trial... demonstrated weight reduction that has not been previously demonstrated in phase III obesity treatment trials... participants who were randomized to the highest dose of tirzepatide (15 mg) lost 20.9% of their body weight, whereas the placebo group lost 3.1% (treatment difference of 17.8%)
Why this rating
Based on Phase III SURMOUNT-1 trial with 2,539 participants.
Source
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff et al. · Annual Review of Medicine · 2023
DOI 10.1146/annurev-med-043021-014919
narrative_reviewCited 148×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide produce significant, sustained weight reduction in adults with obesity by acting on the gut-brain axis to reduce appetite and food intake.Strong
- Combining amylin receptor agonist (cagrilintide) with GLP-1 RA (semaglutide) results in greater weight reduction than semaglutide monotherapy.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →